Wednesday Aug 6
Actavis welcomes AZ in boosting its LAMA/LABA
Actavis says it is excited to partner with AstraZeneca over its long-acting muscarinic antagonist/beta-agonist fixed dose combination respiratory drug following the latter's acquisition of Almirall.
AstraZeneca coughs up $875m for Almirall to support asthma/COPD pipeline
The total price of the Barcelona, Spain-headquartered pharma firm could reach $1.22bn following development, launch, and sales-related milestones, but its respiratory assets will strengthen the Pharma Giant's inhaled asthma and COPD portfolio, adding to the inhaler and particle technology acquired in the $1.5bn Pearl Therapeutics transaction in ... (more)
Big News Network.com
AstraZeneca agrees to strategic transaction with Almirall in respiratory disease
Our eNewspaper network was founded in 2002 to provide stand-alone digital news sites tailored for the most searched-for locations for news.
AstraZeneca stocks respiratory and cancer pipelines
AstraZeneca has agreed to buy Spanish firm Almirall's respiratory drug assets for $875 million up front, plus up to $1.2 billion in performance milestone payments.
Strategic Respiratory Transaction with Almirall
ASTRAZENECA AGREES STRATEGIC TRANSACTION WITH ALMIRALL IN RESPIRATORY DISEASE Business combination will provide boost to revenue as well as creating long-term value, strengthening AstraZeneca's respiratory franchise with a complementary pipeline and inhaled device capabilities in asthma and COPD AstraZeneca today announced that it has entered an ... (more)